NASDAQ:OBLN - Obalon Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.54 +0.04 (+1.60 %)
(As of 05/27/2018 07:55 AM ET)
Previous Close$2.54
Today's Range$2.50 - $2.54
52-Week Range$2.46 - $11.95
Volume36,275 shs
Average Volume98,197 shs
Market Capitalization$44.64 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.37

About Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics logoObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OBLN
CUSIPN/A
Phone760-795-6558

Debt

Debt-to-Equity Ratio0.29
Current Ratio4.29
Quick Ratio4.09

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.91 million
Price / Sales4.50
Cash FlowN/A
Price / CashN/A
Book Value$1.39 per share
Price / Book1.83

Profitability

EPS (Most Recent Fiscal Year)($2.08)
Net Income$-34,760,000.00
Net Margins-399.94%
Return on Equity-102.17%
Return on Assets-71.95%

Miscellaneous

Employees113
Outstanding Shares17,570,000

Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics Inc (NASDAQ:OBLN) issued its quarterly earnings data on Monday, March, 5th. The company reported ($0.60) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.12. The business earned $3.69 million during the quarter, compared to analyst estimates of $3.88 million. Obalon Therapeutics had a negative net margin of 399.94% and a negative return on equity of 102.17%. View Obalon Therapeutics' Earnings History.

When is Obalon Therapeutics' next earnings date?

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Obalon Therapeutics.

What price target have analysts set for OBLN?

5 equities research analysts have issued 1-year price objectives for Obalon Therapeutics' stock. Their predictions range from $4.00 to $16.00. On average, they anticipate Obalon Therapeutics' stock price to reach $9.25 in the next year. View Analyst Ratings for Obalon Therapeutics.

What are Wall Street analysts saying about Obalon Therapeutics stock?

Here are some recent quotes from research analysts about Obalon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (5/16/2018)
  • 2. Northland Securities analysts commented, "We have reached out to management, but have not heard back yet. As we have said multiple times in our notes, we are persona non grata with the company, hence are not hopeful that we can have adequate answers to our questions, which are: What specifically is the allegation? Is it about channel stuffing? Is it about revenue recognition? As highlighted in our Dec 6, 2017 research note, we had questions about Obalon’s revenue recognition criteria, and how the accounting for deliverables was being done. A key question for us is…who knew what & when? Is there any truth to the whistleblower allegations, whatever they may be? As a reminder, Obalon’s new marketing program was implemented at start of Q4-17." (1/23/2018)

Who are some of Obalon Therapeutics' key competitors?

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the folowing people:
  • Mr. Andrew P. Rasdal, Pres, CEO & Director (Age 60)
  • Mr. William John Plovanic CFA, CFO & Sec. (Age 49)
  • Mr. Mark C. Brister, Chief Technology Officer (Age 56)
  • Dr. Kelly Huang Ph.D., Chief Operating Officer (Age 49)
  • Ms. Nooshin Hussainy, VP of Fin. & Principal Accounting Officer (Age 60)

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Has Obalon Therapeutics been receiving favorable news coverage?

News coverage about OBLN stock has trended positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Obalon Therapeutics earned a media sentiment score of 0.42 on Accern's scale. They also assigned news articles about the company an impact score of 46.47 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Obalon Therapeutics' major shareholders?

Obalon Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Tamarack Advisers LP (2.42%), Massachusetts Financial Services Co. MA (1.78%), C WorldWide Group Holding A S (1.41%), Tiverton Asset Management LLC (0.43%) and Granite Investment Partners LLC (0.27%). Company insiders that own Obalon Therapeutics stock include Kim P Kamdar, Matthew Norwood, Neil Drake and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.

Which institutional investors are selling Obalon Therapeutics stock?

OBLN stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Tamarack Advisers LP, Granite Investment Partners LLC, C WorldWide Group Holding A S and Tiverton Asset Management LLC. View Insider Buying and Selling for Obalon Therapeutics.

How do I buy shares of Obalon Therapeutics?

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Obalon Therapeutics' stock price today?

One share of OBLN stock can currently be purchased for approximately $2.54.

How big of a company is Obalon Therapeutics?

Obalon Therapeutics has a market capitalization of $44.64 million and generates $9.91 million in revenue each year. The company earns $-34,760,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Obalon Therapeutics employs 113 workers across the globe.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 760-795-6558 or via email at [email protected]


MarketBeat Community Rating for Obalon Therapeutics (OBLN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Obalon Therapeutics (NASDAQ:OBLN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Obalon Therapeutics in the last 12 months. Their average twelve-month price target is $9.25, suggesting that the stock has a possible upside of 264.17%. The high price target for OBLN is $16.00 and the low price target for OBLN is $4.00. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.402.802.752.50
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.25$9.25$11.50$13.00
Price Target Upside: 264.17% upside139.64% upside171.87% upside67.10% upside

Obalon Therapeutics (NASDAQ:OBLN) Consensus Price Target History

Price Target History for Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics (NASDAQ:OBLN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018Stifel NicolausDowngradeBuy ➝ HoldLowView Rating Details
5/11/2018Northland SecuritiesDowngradeMarket Perform ➝ UnderperformHighView Rating Details
3/6/2018BTIG ResearchLower Price TargetBuy$7.00HighView Rating Details
3/6/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$11.00 ➝ $10.00HighView Rating Details
11/10/2017UBSLower Price TargetBuy$20.00 ➝ $16.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Obalon Therapeutics (NASDAQ:OBLN) Earnings History and Estimates Chart

Earnings by Quarter for Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics (NASDAQ:OBLN) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.19 EPS
Next Year EPS Consensus Estimate: $-2.03 EPS

Obalon Therapeutics (NASDAQ OBLN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018($0.51)N/AView Earnings Details
5/10/2018Q1 2018($0.54)($0.71)$3.55 million$1.35 millionViewN/AView Earnings Details
3/5/2018Q4 2017($0.48)($0.60)$3.88 million$3.69 millionViewListenView Earnings Details
11/3/2017Q3 2017($0.43)($0.55)$2.95 million$2.79 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.43)($0.46)$1.77 million$1.96 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.33)($0.47)$1.60 million$1.47 millionViewN/AView Earnings Details
2/23/2017Q4 2016($0.33)($0.51)$0.70 million$0.77 millionViewN/AView Earnings Details
11/11/2016Q3 2016($0.32)($5.46)$0.70 million$0.77 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Obalon Therapeutics (NASDAQ:OBLN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Obalon Therapeutics (NASDAQ OBLN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.40%
Institutional Ownership Percentage: 36.27%
Insider Trading History for Obalon Therapeutics (NASDAQ:OBLN)
Insider Trading History for Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics (NASDAQ OBLN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Neil DrakeVPBuy5,000$3.96$19,800.00View SEC Filing  
3/14/2018William J PlovanicCFOBuy30,000$4.04$121,200.00View SEC Filing  
10/12/2016Kim P KamdarDirectorBuy13,400$15.00$201,000.00View SEC Filing  
10/12/2016Matthew NorwoodVPBuy1,000$15.00$15,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Obalon Therapeutics (NASDAQ OBLN) News Headlines

Source:
DateHeadline
Obalon Therapeutics Inc. (OBLN) Given Average Rating of "Hold" by BrokeragesObalon Therapeutics Inc. (OBLN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 21 at 3:40 AM
Zacks Investment Research Lowers Obalon Therapeutics (OBLN) to SellZacks Investment Research Lowers Obalon Therapeutics (OBLN) to Sell
www.americanbankingnews.com - May 16 at 11:29 AM
$3.80 Million in Sales Expected for Obalon Therapeutics Inc. (OBLN) This Quarter$3.80 Million in Sales Expected for Obalon Therapeutics Inc. (OBLN) This Quarter
www.americanbankingnews.com - May 14 at 5:05 AM
Obalon Therapeutics (OBLN) CEO Andrew Rasdal on Q1 2018 Results - Earnings Call TranscriptObalon Therapeutics' (OBLN) CEO Andrew Rasdal on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 4:16 PM
UPDATE: Stifel Downgrades Obalon Therapeutics (OBLN) to HoldUPDATE: Stifel Downgrades Obalon Therapeutics (OBLN) to Hold
www.streetinsider.com - May 12 at 10:24 AM
Head to Head Survey: Obalon Therapeutics (OBLN) versus Fresenius (FSNUY)Head to Head Survey: Obalon Therapeutics (OBLN) versus Fresenius (FSNUY)
www.americanbankingnews.com - May 12 at 10:03 AM
 Analysts Expect Obalon Therapeutics Inc. (OBLN) to Announce -$0.51 EPS Analysts Expect Obalon Therapeutics Inc. (OBLN) to Announce -$0.51 EPS
www.americanbankingnews.com - May 12 at 1:12 AM
Obalon Therapeutics (OBLN) Cut to Underperform at Northland SecuritiesObalon Therapeutics (OBLN) Cut to Underperform at Northland Securities
www.americanbankingnews.com - May 11 at 5:49 PM
Obalon Therapeutics (OBLN) Downgraded by Stifel Nicolaus to "Hold"Obalon Therapeutics (OBLN) Downgraded by Stifel Nicolaus to "Hold"
www.americanbankingnews.com - May 11 at 5:43 PM
UPDATE: Northland Capital Markets Downgrades Obalon Therapeutics (OBLN) to Underperform; Something is Not RightUPDATE: Northland Capital Markets Downgrades Obalon Therapeutics (OBLN) to Underperform; 'Something is Not Right'
www.streetinsider.com - May 11 at 4:18 PM
Obalon Therapeutics misses by $0.21, misses on revenueObalon Therapeutics misses by $0.21, misses on revenue
seekingalpha.com - May 11 at 10:42 AM
Obalon Therapeutics (OBLN) Announces Quarterly  Earnings ResultsObalon Therapeutics (OBLN) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 6:51 PM
Obalon Announces First Quarter 2018 Financial ResultsObalon Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 4:23 PM
Todd Wood joins Obalon Therapeutics, Inc. as Vice President Global SalesTodd Wood joins Obalon Therapeutics, Inc. as Vice President Global Sales
finance.yahoo.com - May 7 at 4:25 PM
Obalon Therapeutics (OBLN) Rating Increased to Hold at ValuEngineObalon Therapeutics (OBLN) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 11:07 PM
Obalon Therapeutics (OBLN) Scheduled to Post Earnings on TuesdayObalon Therapeutics (OBLN) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 1 at 2:08 AM
Obalon Therapeutics (OBLN) Rating Increased to Hold at Zacks Investment ResearchObalon Therapeutics (OBLN) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 27 at 6:26 AM
Obalon Therapeutics Inc. (OBLN) Receives Consensus Recommendation of "Hold" from AnalystsObalon Therapeutics Inc. (OBLN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 26 at 3:50 AM
$3.55 Million in Sales Expected for Obalon Therapeutics Inc. (OBLN) This Quarter$3.55 Million in Sales Expected for Obalon Therapeutics Inc. (OBLN) This Quarter
www.americanbankingnews.com - April 26 at 2:38 AM
Obalon Therapeutics Inc. (OBLN) Expected to Post Earnings of -$0.54 Per ShareObalon Therapeutics Inc. (OBLN) Expected to Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 24 at 3:12 PM
Obalon Therapeutics (OBLN) Upgraded at Zacks Investment ResearchObalon Therapeutics (OBLN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 20 at 7:02 AM
AtriCure (ATRC) vs. Obalon Therapeutics (OBLN) Head-To-Head SurveyAtriCure (ATRC) vs. Obalon Therapeutics (OBLN) Head-To-Head Survey
www.americanbankingnews.com - April 17 at 1:52 AM
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The FirmDEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 16 at 4:14 PM
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The FirmDEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 13 at 4:18 PM
Obalon Therapeutics (OBLN) Rating Reiterated by UBSObalon Therapeutics (OBLN) Rating Reiterated by UBS
www.americanbankingnews.com - April 13 at 1:00 PM
April 16th Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Obalon Therapeutics, Inc. (OBLN)April 16th Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Obalon Therapeutics, Inc. (OBLN)
finance.yahoo.com - April 13 at 10:09 AM
Obalon Therapeutics (OBLN) Downgraded to Sell at Zacks Investment ResearchObalon Therapeutics (OBLN) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 12 at 9:35 PM
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Obalon Therapeutics, Inc. (OBLN) and April 16 Lead Plaintiff DeadlineScott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Obalon Therapeutics, Inc. (OBLN) and April 16 Lead Plaintiff Deadline
finance.yahoo.com - April 12 at 4:16 PM
4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 12 at 4:16 PM
Obalon Therapeutics (OBLN) Buy Rating Reaffirmed at UBSObalon Therapeutics' (OBLN) Buy Rating Reaffirmed at UBS
www.americanbankingnews.com - April 12 at 3:58 PM
Glancy Prongay & Murray LLP Reminds Investors of the April 16, 2018 Deadline in the Class Action Lawsuit Against Obalon Therapeutics, Inc. (OBLN)Glancy Prongay & Murray LLP Reminds Investors of the April 16, 2018 Deadline in the Class Action Lawsuit Against Obalon Therapeutics, Inc. (OBLN)
finance.yahoo.com - April 11 at 10:22 AM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Obalon Therapeutics, Inc. (OBLN) & Lead Plaintiff Deadline - April 16, 2018DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Obalon Therapeutics, Inc. (OBLN) & Lead Plaintiff Deadline - April 16, 2018
finance.yahoo.com - April 11 at 10:22 AM
6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 10 at 4:17 PM
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN) and Encourages Investors to Contact the Firm ...Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN) and Encourages Investors to Contact the Firm ...
www.businesswire.com - April 10 at 10:07 AM
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN) and Encourages Investors to Contact the Firm Before April 16thBragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN) and Encourages Investors to Contact the Firm Before April 16th
finance.yahoo.com - April 10 at 10:07 AM
FINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Obalon Therapeutics, Inc. (Nasdaq: OBLN) To Contact The FirmFINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Obalon Therapeutics, Inc. (Nasdaq: OBLN) To Contact The Firm
finance.yahoo.com - April 9 at 4:15 PM
APRIL 16 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The FirmAPRIL 16 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 9 at 4:15 PM
DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The FirmDEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 7 at 5:17 PM
IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. And Reminds Investors With Losses In Excess of $50,000 to Contact The FirmIMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. And Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 5 at 4:16 PM
Obalon Therapeutics (OBLN) Cut to Sell at Zacks Investment ResearchObalon Therapeutics (OBLN) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - April 1 at 11:52 AM
Obalon Therapeutics Inc. (OBLN) Receives Consensus Rating of "Hold" from AnalystsObalon Therapeutics Inc. (OBLN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 3:26 AM
IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. And Reminds Investors to ContactThe FirmIMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. And Reminds Investors to ContactThe Firm
finance.yahoo.com - March 31 at 4:14 PM
Obalon Therapeutics (OBLN) Raised to "Buy" at Zacks Investment ResearchObalon Therapeutics (OBLN) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:00 AM
Obalon Therapeutics (OBLN) Receives "Buy" Rating from Canaccord GenuityObalon Therapeutics (OBLN) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - March 27 at 10:01 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Obalon Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – OBLNSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Obalon Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – OBLN
finance.yahoo.com - March 25 at 10:00 AM
$3.55 Million in Sales Expected for Obalon Therapeutics Inc (OBLN) This Quarter$3.55 Million in Sales Expected for Obalon Therapeutics Inc (OBLN) This Quarter
www.americanbankingnews.com - March 23 at 4:00 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Obalon Therapeutics, Inc. (OBLN) & Lead Plaintiff Deadline - April 16, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Obalon Therapeutics, Inc. (OBLN) & Lead Plaintiff Deadline - April 16, 2018
finance.yahoo.com - March 22 at 4:13 PM
OBLN NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. - OBLNOBLN NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. - OBLN
finance.yahoo.com - March 22 at 4:13 PM
Neil Drake Acquires 5,000 Shares of Obalon Therapeutics Inc (OBLN) StockNeil Drake Acquires 5,000 Shares of Obalon Therapeutics Inc (OBLN) Stock
www.americanbankingnews.com - March 19 at 8:30 PM
With A -69.86% Earnings Drop, Did Obalon Therapeutics Inc (NASDAQ:OBLN) Really Underperform?With A -69.86% Earnings Drop, Did Obalon Therapeutics Inc (NASDAQ:OBLN) Really Underperform?
finance.yahoo.com - March 17 at 9:56 AM

SEC Filings

Obalon Therapeutics (NASDAQ:OBLN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Obalon Therapeutics (NASDAQ:OBLN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Obalon Therapeutics (NASDAQ OBLN) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.